Pharma BD Deal Intelligence
Roche and Foundation Medicine entered a broad strategic collaboration for companion diagnostics and molecular information services. Roche acquired a 56.3% ownership stake in Foundation Medicine for $50/share ($1.03B) and the companies agreed to co-develop next-generation companion diagnostics and molecular profiling products. This licensing/partnership deal gave Roche access to FMI's genomic profiling platform for drug development. Roche later acquired the remaining shares in 2018.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Roche Holding AG / Foundation Medicine, Inc. (this deal) | 2015 | $1.1B | 87 |
| Roche Holding AG / Chugai Pharmaceutical Co. Ltd. | 2002 | $1.4B | 100 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2008 | $3.4B | 88 |
| Roche Holding AG / Corange Ltd. (Boehringer Mannheim Group) | 1997 | $11.0B | 88 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2007 | $3.4B | 88 |
| Roche Holding AG / Foundation Medicine, Inc. | 2018 | $5.3B | 85 |
| Roche Holding AG / GlycArt Biotechnology AG | 2005 | $182M | 80 |
← Browse all deals · How we score deals
More: 2015 deals · Roche Holding AG deals · Oncology deals